Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,114,582
  • Shares Outstanding, K 145,597
  • Annual Sales, $ 9,836 M
  • Annual Income, $ 1,161 M
  • 60-Month Beta -0.04
  • Price/Sales 3.35
  • Price/Cash Flow 12.17
  • Price/Book 2.15
Trade BIIB with:

Options Overview Details

View History
  • Implied Volatility 43.85% ( -3.79%)
  • Historical Volatility 31.17%
  • IV Percentile 99%
  • IV Rank 86.51%
  • IV High 47.65% on 07/25/24
  • IV Low 19.53% on 09/12/23
  • Put/Call Vol Ratio 0.74
  • Today's Volume 3,130
  • Volume Avg (30-Day) 1,435
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 33,532
  • Open Int (30-Day) 37,107

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 4.00
  • Number of Estimates 26
  • High Estimate 6.04
  • Low Estimate 3.46
  • Prior Year 4.02
  • Growth Rate Est. (year over year) -0.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
210.00 +0.56%
on 07/26/24
238.00 -11.27%
on 07/12/24
-13.29 (-5.92%)
since 06/26/24
3-Month
208.54 +1.26%
on 04/29/24
238.00 -11.27%
on 07/12/24
+2.27 (+1.09%)
since 04/26/24
52-Week
189.44 +11.47%
on 04/19/24
278.95 -24.30%
on 08/08/23
-54.08 (-20.39%)
since 07/26/23

Most Recent Stories

More News
Stocks Rebound Higher as Deflator Report Supports Fed Rate-Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) on Friday rose +1.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +1.03%. US stocks Friday rebounded higher...

$SPX : 5,459.10 (+1.11%)
SPY : 544.44 (+1.12%)
$DOWI : 40,589.34 (+1.64%)
DIA : 405.97 (+1.62%)
$IUXX : 19,023.66 (+1.03%)
QQQ : 462.97 (+1.03%)
MSFT : 425.27 (+1.64%)
META : 465.70 (+2.71%)
SPOT : 321.88 (-2.15%)
AMZN : 182.50 (+1.47%)
NVDA : 113.06 (+0.69%)
TSLA : 219.80 (-0.20%)
Stocks Rebound Higher as Deflator Report Supports Fed Rate-Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) today is up +0.88%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.65%. US stocks today rebounded higher...

$SPX : 5,459.10 (+1.11%)
SPY : 544.44 (+1.12%)
$DOWI : 40,589.34 (+1.64%)
DIA : 405.97 (+1.62%)
$IUXX : 19,023.66 (+1.03%)
QQQ : 462.97 (+1.03%)
MSFT : 425.27 (+1.64%)
META : 465.70 (+2.71%)
SPOT : 321.88 (-2.15%)
AMZN : 182.50 (+1.47%)
NVDA : 113.06 (+0.69%)
TSLA : 219.80 (-0.20%)
Stocks Rebound Higher as Deflator Report Supports Fed Rate-Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) today is up +0.87%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.82%. US stocks today rebounded higher...

$SPX : 5,459.10 (+1.11%)
SPY : 544.44 (+1.12%)
$DOWI : 40,589.34 (+1.64%)
DIA : 405.97 (+1.62%)
$IUXX : 19,023.66 (+1.03%)
QQQ : 462.97 (+1.03%)
MSFT : 425.27 (+1.64%)
META : 465.70 (+2.71%)
SPOT : 321.88 (-2.15%)
AMZN : 182.50 (+1.47%)
NVDA : 113.06 (+0.69%)
TSLA : 219.80 (-0.20%)
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval

Shares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval

BIIB : 211.17 (-7.15%)
Biogen Earnings Preview: What to Expect

Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

BIIB : 211.17 (-7.15%)
$SPX : 5,459.10 (+1.11%)
BBH : 179.06 (+0.73%)
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

Revenue is climbing at these two drug companies -- and the trend should continue.

WMT : 69.78 (-0.34%)
CMG : 49.83 (-1.95%)
NVO : 126.73 (-0.88%)
NVDA : 113.06 (+0.69%)
REGN : 1,078.63 (+1.36%)
BIIB : 211.17 (-7.15%)
AMGN : 334.85 (+0.16%)
LLY : 804.62 (-2.02%)
VRTX : 495.26 (+0.61%)
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?

Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.

JPM : 212.24 (+1.71%)
NVO : 126.73 (-0.88%)
BIIB : 211.17 (-7.15%)
LLY : 804.62 (-2.02%)
3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

NVDA : 113.06 (+0.69%)
MSFT : 425.27 (+1.64%)
META : 465.70 (+2.71%)
AMZN : 182.50 (+1.47%)
GOOGL : 167.00 (-0.17%)
AVGO : 151.63 (+1.59%)
AAPL : 217.96 (+0.22%)
TSLA : 219.80 (-0.20%)
GS : 499.03 (+1.49%)
LLY : 804.62 (-2.02%)
BIIB : 211.17 (-7.15%)
This Is Massive News for Eli Lilly Investors

A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.

NVO : 126.73 (-0.88%)
BIIB : 211.17 (-7.15%)
LLY : 804.62 (-2.02%)
Is Biogen Stock Underperforming the Nasdaq?

Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.

BIIB : 211.17 (-7.15%)
$NASX : 17,357.88 (+1.03%)
VRTX : 495.26 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 223.33
2nd Resistance Point 220.43
1st Resistance Point 215.80
Last Price 211.17
1st Support Level 208.27
2nd Support Level 205.37
3rd Support Level 200.74

See More

52-Week High 278.95
Fibonacci 61.8% 244.76
Fibonacci 50% 234.20
Fibonacci 38.2% 223.63
Last Price 211.17
52-Week Low 189.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar